{"id":"salbutamol-hfa-134a","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nervousness"},{"rate":"1-3","effect":"Palpitations"},{"rate":"1-3","effect":"Muscle cramps"},{"rate":"1-3","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Salbutamol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering increased intracellular cAMP levels and smooth muscle relaxation. This leads to rapid airway dilation and relief of bronchoconstriction. The HFA-134a formulation refers to the hydrofluoroalkane propellant used in the metered-dose inhaler.","oneSentence":"Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:47.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm and reversible airway obstruction in asthma"},{"name":"Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction"}]},"trialDetails":[{"nctId":"NCT06261957","phase":"PHASE3","title":"A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-31","conditions":"Asthma","enrollment":477},{"nctId":"NCT06433908","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-06-04","conditions":"Asthma, Healthy Participants","enrollment":60},{"nctId":"NCT06433921","phase":"PHASE1","title":"A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-14","conditions":"Asthma, Mild Asthma","enrollment":84},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":"Primary Ciliary Dyskinesia","enrollment":27},{"nctId":"NCT05791565","phase":"PHASE1","title":"Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-04-03","conditions":"Asthma","enrollment":28},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT00085774","phase":"PHASE3","title":"Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-06-30","conditions":"Exercise-induced Bronchospasm","enrollment":24},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT02126839","phase":"PHASE3","title":"A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05","conditions":"Asthma","enrollment":186},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT04584034","phase":"PHASE4","title":"Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial","status":"WITHDRAWN","sponsor":"UMC Utrecht","startDate":"2021-09","conditions":"Wheezing","enrollment":""},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT03371459","phase":"PHASE2","title":"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-29","conditions":"Asthma","enrollment":46},{"nctId":"NCT00394329","phase":"PHASE3","title":"(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2006-11","conditions":"Asthma","enrollment":288},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT00901368","phase":"PHASE4","title":"FACTO Study (Foster® As Complete Treatment Option)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-05","conditions":"Asthmatic Patients","enrollment":431},{"nctId":"NCT00384189","phase":"PHASE3","title":"A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma","enrollment":1080},{"nctId":"NCT00441441","phase":"PHASE3","title":"A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Asthma","enrollment":351},{"nctId":"NCT00350207","phase":"PHASE2","title":"Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-07","conditions":"Asthma","enrollment":388},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT01844401","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-04","conditions":"Asthma","enrollment":15},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01302587","phase":"","title":"A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-03","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema","enrollment":306},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Salbutamol HFA-134a","genericName":"Salbutamol HFA-134a","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}